Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM)

M. Q. Lacy, S. R. Hayman, M. A. Gertz, K. D. Short, A. Dispenzieri, S. Kumar, P. R. Greipp, J. A. Lust, S. J. Russell, D. Dingli, S. Zeldenrust, R. Fonseca, P. L. Bergsagel, V. Roy, J. R. Mikhael, A. K. Stewart, K. Laumann, J. B. Allred, S. J. Mandrekar, S. V. RajkumarF. Buadi

Research output: Contribution to journal › Article › peer-review

164 Scopus citations

Fingerprint

Dive into the research topics of 'Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM)'. Together they form a unique fingerprint.

Medicine & Life Sciences